He said he expects Celltrion's trastuzumab will be up to 50% cheaper than Roche's subcutaneous (SC) Herceptin. However this still won't be enough to persuade healthcare systems or patients to go ...

Here are the top 5 biosimilar articles for the week of April 21, 2025. Number 5: Trastuzumab biosimilars saw significant ...

Celltrion’s biosimilar marketing strategy ... and its biosimilar of Roche’s breast cancer blockbuster, Herceptin (trastuzumab). A spokesperson said at the time: "Remsima, the first-choice ...

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply ...

JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA ® (ustekinumab-stba), a biosimilar to STELARA ® (ustekinumab) has been added to the Costco Member ...

Celltrion will cancel treasury shares worth 203.3 billion won ($140 million) to enhance shareholder value, the Korean ...

Korean pharmaceutical giant Celltrion on Tuesday pledged to achieve an annual growth rate of 30 percent and a return on equity of at least 7 percent by 2027, as part of its long-term initiative ...

The US Food and Drug Administration (FDA) has designated Celltrion’s Yuflyma (adalimumab-aaty) as an interchangeable biosimilar to AbbVie’s Humira (adalimumab). The decision allows Yuflyma to be ...

JERSEY CITY, N.J., March 10, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO ® (omalizumab-igec) as the first and only biosimilar designated ...

Celltrion directly requested individual shareholders to terminate contracts, noting that lending transactions increase stock price volatility. The bio leader Celltrion was one of the heavily ...